Lung adenocarcinoma patient derived organoids were used to identify effective anti-cancer drugs poziotinib and pralsetinib for ERBB2 exon 20 insertions and RET fusions, respectively (Kim et al., 2021). The gene discussed is RET; the disease is lung adenocarcinoma.